[go: up one dir, main page]

BRPI0406701A - Compostos tricìclicos inibidores da proteìna cinase para melhorar a eficácia de agentes antineoplásicos e da terapia de radiação - Google Patents

Compostos tricìclicos inibidores da proteìna cinase para melhorar a eficácia de agentes antineoplásicos e da terapia de radiação

Info

Publication number
BRPI0406701A
BRPI0406701A BR0406701-0A BRPI0406701A BRPI0406701A BR PI0406701 A BRPI0406701 A BR PI0406701A BR PI0406701 A BRPI0406701 A BR PI0406701A BR PI0406701 A BRPI0406701 A BR PI0406701A
Authority
BR
Brazil
Prior art keywords
protein kinase
improve
radiation therapy
effectiveness
tricyclic
Prior art date
Application number
BR0406701-0A
Other languages
English (en)
Inventor
Sacha Ninkovic
Michael John Bennett
Eugene Yuanjin Rui
Fen Wang
Suzanne Pritchett Benedict
Min Teng
Yong Wang
Jinjiang Zhu
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BRPI0406701A publication Critical patent/BRPI0406701A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPOSTOS TRICìCLICOS INIBIDORES DA PROTEìNA CINASE PARA MELHORAR A EFICáCIA DE AGENTES AN-TINEOPLáSICOS E DA TERAPIA DE RADIAçãO". A presente invenção refere-se a compostos tricíclicos inibidores de proteína cinase, tais como CHK-1, da fórmula seguinte (em que R¬ 2¬, R¬ 3¬ e R¬ 4¬ são como definidos na especificação). Composições farmacêuticas contendo quantidades eficazes dos referidos compostos ou dos seus sais que são úteis como um agente sozinho ou associado a um agente antineoplásico ou radiação terapêutica possuindo um efeito antineoplásico para tratar distúrbios ou condições, tais como cânceres.
BR0406701-0A 2003-01-09 2004-01-05 Compostos tricìclicos inibidores da proteìna cinase para melhorar a eficácia de agentes antineoplásicos e da terapia de radiação BRPI0406701A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43939603P 2003-01-09 2003-01-09
PCT/IB2004/000026 WO2004063198A1 (en) 2003-01-09 2004-01-05 Diazepinoindole derivatives as kinase inhibitors

Publications (1)

Publication Number Publication Date
BRPI0406701A true BRPI0406701A (pt) 2005-12-20

Family

ID=32713475

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0406701-0A BRPI0406701A (pt) 2003-01-09 2004-01-05 Compostos tricìclicos inibidores da proteìna cinase para melhorar a eficácia de agentes antineoplásicos e da terapia de radiação

Country Status (34)

Country Link
US (3) US6967198B2 (pt)
EP (2) EP1585749B1 (pt)
JP (1) JP3990718B2 (pt)
KR (1) KR100697746B1 (pt)
CN (1) CN1759118B (pt)
AP (1) AP2048A (pt)
AT (1) ATE404564T1 (pt)
AU (1) AU2004203977B2 (pt)
BR (1) BRPI0406701A (pt)
CA (1) CA2512683C (pt)
CR (1) CR7899A (pt)
CY (1) CY1108408T1 (pt)
DE (1) DE602004015724D1 (pt)
DK (1) DK1585749T3 (pt)
EA (1) EA009337B1 (pt)
EC (1) ECSP055911A (pt)
ES (1) ES2309484T3 (pt)
GE (1) GEP20084367B (pt)
HR (1) HRP20050624A2 (pt)
IL (1) IL169082A (pt)
IS (1) IS7884A (pt)
MA (1) MA27703A1 (pt)
MX (1) MXPA05007352A (pt)
NO (1) NO20053775L (pt)
NZ (1) NZ540638A (pt)
OA (1) OA13017A (pt)
PL (1) PL378372A1 (pt)
PT (1) PT1585749E (pt)
RS (1) RS20050522A (pt)
SI (1) SI1585749T1 (pt)
TN (1) TNSN05176A1 (pt)
UA (1) UA80733C2 (pt)
WO (1) WO2004063198A1 (pt)
ZA (1) ZA200504674B (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6831093B2 (en) * 2002-01-22 2004-12-14 The Regents Of The University Of California Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof
BRPI0406701A (pt) * 2003-01-09 2005-12-20 Pfizer Compostos tricìclicos inibidores da proteìna cinase para melhorar a eficácia de agentes antineoplásicos e da terapia de radiação
MX2007010073A (es) * 2005-02-18 2007-10-10 Astrazeneca Ab Metodo para determinar la respuesta de los inhibidores de chk1.
EP2330105A1 (en) 2005-03-29 2011-06-08 ICOS Corporation Heteroaryl urea derivatives useful for inhibiting CHK1
GB0510390D0 (en) * 2005-05-20 2005-06-29 Novartis Ag Organic compounds
SI1896040T1 (sl) 2005-06-29 2012-12-31 Threshold Pharmaceuticals, Inc. Fosforamidatna alkilatorska predzdravila
CN101384614A (zh) * 2005-08-15 2009-03-11 加利福尼亚大学董事会 Vegf活化的fas配体
WO2007023948A1 (ja) 2005-08-25 2007-03-01 Ube Industries, Ltd. 光学活性（Ｓ又はＲ）－α－アミノ酸及び光学活性（Ｒ又はＳ）－α－アミノ酸エステルの製造方法
JP2009506077A (ja) * 2005-08-26 2009-02-12 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 非ステロイド性抗アンドロゲン剤
CA2648371A1 (en) * 2006-04-04 2007-10-11 Pfizer Products Inc. Combination therapy of (2r,z)-2-amino-2-cyclohexyl-n-(5-(1-methyl-1h-pyrazol-4-yl)-1-oxo-2,6-dihydro-1h-[1,2]diazepino[4,5,6-cd]indol-8-yl)acetamide
WO2007113647A1 (en) * 2006-04-04 2007-10-11 Pfizer Products Inc. Polymorphic forms of (2r,z)-2-amino-2-cyclohexyl-n-(5-(1-methyl-1h-pyrazol-4υl)-1-oxo-2,6-dihydro-1h-[1,2]diazepino[4,5,6-cd]indol-8-yl)acetamide
MX2009005300A (es) * 2006-11-17 2009-06-08 Schering Corp Combinacion de un inhibidor de acido desoxirribonucleico polimerasa-alfa y un inhibidor de una cinasa de punto de verificacion para trastornos proliferativos.
US8158656B2 (en) * 2008-05-16 2012-04-17 Shenzhen Chipscreen Biosciences Ltd. 2-indolinone derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
EP2328890B1 (en) * 2008-08-06 2012-01-25 Pfizer Inc. 6 substituted 2-heterocyclylamino pyrazine compounds as chk-1 inhibitors
WO2010040527A1 (en) * 2008-10-10 2010-04-15 Priaxon Ag Novel compounds which modulate kinase activity
US8314108B2 (en) 2008-12-17 2012-11-20 Eli Lilly And Company 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile, pharmaceutically acceptable salts thereof, or solvate of salts
US8663210B2 (en) 2009-05-13 2014-03-04 Novian Health, Inc. Methods and apparatus for performing interstitial laser therapy and interstitial brachytherapy
US8211901B2 (en) 2009-05-22 2012-07-03 Shenzhen Chipscreen Biosciences Ltd. Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
CN101906076B (zh) 2009-06-04 2013-03-13 深圳微芯生物科技有限责任公司 作为蛋白激酶抑制剂和组蛋白去乙酰化酶抑制剂的萘酰胺衍生物、其制备方法及应用
CN103748094B (zh) 2011-05-06 2016-06-29 扎夫根股份有限公司 三环磺酰胺化合物及其制备和使用方法
EP2793882A4 (en) * 2011-12-22 2015-04-29 Threshold Pharmaceuticals Inc ADMINISTRATION OF HYPOXIA-ACTIVATED PRODRUGS IN COMBINATION WITH CHK1 INHIBITORS FOR THE TREATMENT OF CANCER
EP2797919B1 (en) 2011-12-31 2017-03-29 BeiGene, Ltd. Fused tetra or penta-cyclic pyridophthalazinones as parp inhibitors
HUE035153T2 (en) * 2011-12-31 2018-05-02 Beigene Ltd Condensed tetra- or pentacyclic dihydrodiazepinocarbazolone derivatives as PARP inhibitors
CN102746211B (zh) * 2012-06-27 2015-05-27 上海泰坦化学有限公司 一种取代吲哚-3-甲醛类化合物的制备方法
TWI633107B (zh) * 2013-05-22 2018-08-21 開曼群島商百濟神州生物科技有限公司 作為ｐａｒｐ抑制劑的稠合四或五環二氫二氮呯并咔唑酮
WO2015013579A1 (en) 2013-07-26 2015-01-29 Update Pharma Inc. Compositions to improve the therapeutic benefit of bisantrene
US10071109B2 (en) 2013-11-06 2018-09-11 Molecular Templates, Inc. Predictive biomarker for hypoxia-activated prodrug therapy
HRP20191375T1 (hr) 2014-06-17 2019-11-01 Vertex Pharma Postupak liječenja raka upotrebom kombinacije chk1 i atr inhibitora
NZ739876A (en) * 2015-08-25 2022-09-30 Beigene Ltd Process for preparing parp inhibitor, crystalline forms, and uses thereof
RU2768621C1 (ru) 2015-09-30 2022-03-24 Вертекс Фармасьютикалз Инкорпорейтед Способ лечения рака с использованием комбинации повреждающих днк средств и ингибиторов atr
TWI806840B (zh) 2016-09-27 2023-07-01 英屬開曼群島商百濟神州有限公司 使用包含parp抑制劑的組合產品治療癌症
JP6541635B2 (ja) * 2016-10-28 2019-07-10 ベイジーン リミテッド Ｐａｒｐ阻害剤としての縮合四環式または縮合五環式ジヒドロジアゼピノカルバゾロン
CN115433187B (zh) 2017-02-28 2023-10-27 百济神州(苏州)生物科技有限公司 稠合的四环或五环二氢二氮杂䓬并咔唑酮的盐的结晶形式组合物及其用途
US11661581B2 (en) * 2017-05-25 2023-05-30 University Of Massachusetts Use of CDK inhibitors to enhance growth and self-renewal of progenitor cells
CN111108105B (zh) * 2017-09-22 2023-03-31 朱比兰特埃皮帕德有限公司 作为pad抑制剂的杂环化合物
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
CN113631179A (zh) * 2019-01-25 2021-11-09 努梅迪公司 用于治疗特发性肺纤维化的方法
WO2021018298A1 (zh) * 2019-08-01 2021-02-04 南京明德新药研发有限公司 作为parp抑制剂吲哚并七元酰肟化合物
JP7260718B2 (ja) 2019-11-29 2023-04-18 メッドシャイン ディスカバリー インコーポレイテッド ジアザインドール誘導体及びそのＣｈｋ１阻害剤としての使用
WO2022011458A1 (en) * 2020-07-13 2022-01-20 Ontario Institute For Cancer Research (Oicr) Nicotinamide phosphoribosyltransferase (nampt) inhibitor-conjugates and uses thereof
TW202214649A (zh) * 2020-07-31 2022-04-16 大陸商正大天晴藥業集團股份有限公司 用作ｐａｒｐ抑制劑的吲哚并七員醯肟類似物的結晶及其製備方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9722320D0 (en) 1997-10-22 1997-12-17 Janssen Pharmaceutica Nv Human cell cycle checkpoint proteins
US6383744B1 (en) 1998-07-10 2002-05-07 Incyte Genomics, Inc. Human checkpoint kinase
EP1135135A4 (en) 1998-09-18 2006-08-09 Smithkline Beecham Corp CHK1 KINASE INHIBITORS
HRP20010573B1 (en) 1999-01-11 2006-04-30 Agouron Pharmaceuticals Tricyclic inhibitors of poly(adp-ribose) polymerases
PT1144609E (pt) 1999-08-27 2008-05-28 Novartis Vaccines & Diagnostic Oligonucleótidos anti-sentido quiméricos e suas formulações para transfecção de células
ECSP003637A (es) 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
US6670167B1 (en) 1999-11-01 2003-12-30 Agouron Pharmaceuticals, Inc. Catalytic domain of the human effector cell cycle checkpoint protein kinase materials and methods for identification of inhibitors thereof
ES2239037T3 (es) 1999-09-22 2005-09-16 Canbas Co., Ltd. Metodos y composiciones para inhibir la deteccion del ciclo celular en g2 y sensibilizar celulas a agentes dañinos del dna.
US6211164B1 (en) 2000-03-10 2001-04-03 Abbott Laboratories Antisense oligonucleotides of the human chk1 gene and uses thereof
US6887996B2 (en) 2000-12-01 2005-05-03 Guilford Pharmaceuticals Inc. Compounds and their use
UA76977C2 (en) 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
BRPI0406701A (pt) * 2003-01-09 2005-12-20 Pfizer Compostos tricìclicos inibidores da proteìna cinase para melhorar a eficácia de agentes antineoplásicos e da terapia de radiação

Also Published As

Publication number Publication date
US20060004052A1 (en) 2006-01-05
IS7884A (is) 2005-06-09
JP3990718B2 (ja) 2007-10-17
US7462713B2 (en) 2008-12-09
CY1108408T1 (el) 2014-02-12
KR20050092397A (ko) 2005-09-21
PT1585749E (pt) 2008-10-23
RS20050522A (sr) 2007-12-31
TNSN05176A1 (fr) 2007-06-11
CN1759118A (zh) 2006-04-12
EP1947102A1 (en) 2008-07-23
PL378372A1 (pl) 2006-04-03
IL169082A (en) 2011-02-28
MA27703A1 (fr) 2006-01-02
ATE404564T1 (de) 2008-08-15
CA2512683A1 (en) 2004-07-29
ECSP055911A (es) 2005-11-22
EP1585749A1 (en) 2005-10-19
UA80733C2 (en) 2007-10-25
DK1585749T3 (da) 2008-09-22
NO20053775D0 (no) 2005-08-08
NZ540638A (en) 2007-12-21
HRP20050624A2 (en) 2006-02-28
WO2004063198A1 (en) 2004-07-29
EA200500893A1 (ru) 2006-02-24
CN1759118B (zh) 2010-12-08
US20070135415A1 (en) 2007-06-14
OA13017A (en) 2006-11-10
SI1585749T1 (sl) 2008-10-31
KR100697746B1 (ko) 2007-03-22
HK1086257A1 (en) 2006-09-15
DE602004015724D1 (de) 2008-09-25
GEP20084367B (en) 2008-05-13
AP2048A (en) 2009-09-24
ZA200504674B (en) 2006-07-26
US20050075499A1 (en) 2005-04-07
US6967198B2 (en) 2005-11-22
AU2004203977A1 (en) 2004-07-29
EP1585749B1 (en) 2008-08-13
CR7899A (es) 2005-08-05
NO20053775L (no) 2005-09-16
CA2512683C (en) 2010-03-16
EA009337B1 (ru) 2007-12-28
ES2309484T3 (es) 2008-12-16
JP2006516274A (ja) 2006-06-29
AP2005003353A0 (en) 2005-09-30
AU2004203977B2 (en) 2010-06-17
US7132533B2 (en) 2006-11-07
MXPA05007352A (es) 2006-02-17

Similar Documents

Publication Publication Date Title
BRPI0406701A (pt) Compostos tricìclicos inibidores da proteìna cinase para melhorar a eficácia de agentes antineoplásicos e da terapia de radiação
BRPI0407834A (pt) composto, processo para a manufatura do mesmo, composição, processo para a manufatura da mesma, método de tratamento ou prevenção de um distúrbio mediado por proteìna quinase em um indivìduo, uso de um composto, ensaio para determinar a atividade dos compostos, e, método de inibição da atividade ou função de uma proteìna quinase
BR0208373A (pt) Inibidores da tirosina cinase
BR0315912A (pt) Compostos pirimìdicos com atividade antiproliferativa (ii)
BR112012010705A2 (pt) composto, composição farmacêutica, produto farmacêutico combinado, uso de um composto, e, métodos para tratar uma doença ou condição, e para inibir um bromodomínio
BRPI0312464B8 (pt) compostos inibidores de tirosina quinases, composições farmacêuticas compreendendo os mesmos, processos para fabricação e usos dos mesmos
BR112014016163A8 (pt) piridoftalazinonas tetra ou penta-cíclicas fundidas como inibidores de parp
BRPI0108394B8 (pt) inibidores de proteína de quinase de 2-indolinona de pirrol substituído, seus sais e composições farmacêuticas compreendendo os mesmos
BRPI0410913A (pt) benzotiofenos substituìdos com cicloalquil e heterocicloalquil como agentes terapêuticos
ECSP077980A (es) Inhibidores de la actividad akt
BR0012590A (pt) Composto, processo para a preparação do mesmo, formulação farmacêutica, uso de um composto, e, métodos para tratamento ou profilaxia de dor ou desconforto, e para tratamento ou profilaxia de dor neuropática ou central
BRPI0413580A (pt) composto, composição farmacêutica, e, métodos para tratar ou prevenir cáncer em um mamìfero em necessidade de tal tratamento, para modular a formação do fuso mitótico e para inibir a cinesina mitótica ksp
BR0304648A (pt) Combinação de inibidores de ciclooxigenase-2 e talidomida para o tratamento de neoplasia
BRPI0417158A (pt) composto, composição farmacêutica, uso de um composto, método para prevenir, tratar ou melhorar uma doença ou condição associada com angiogênese desregulada, e, métodos para tratar ou melhorar cáncer, para reduzir o potencial metastático de um tumor, e para tratar ou melhorar tumores, e uma condição ou doença
BR0309342A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
BRPI0607927A2 (pt) derivados de pirazol-pirimidina
BRPI0409884A (pt) compostos, composições farmacêuticas, método para o tratamento ou porfilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
BRPI0510657A (pt) tratamento com cisplatina e com um inibidor de egfr
BRPI0411864A (pt) combinação de inibidores de src quinase e agentes quimioterápicos para o tratamento de doenças proliferativas
BR0208353A (pt) Compostos de diidropirimidina substituìdos com ciano e seu uso para tratar doenças
BRPI0410663B8 (pt) compostos de hidroxiamidina e hidroxiguanidina e seus usos
BR0112580A (pt) Compostos, composições farmacêuticas que contêm os mesmos, utilização desses compostos, processo para tratamento terapêutico e/ou profilático e processo para a preparação desses compostos
BRPI0413384A (pt) inibidores da proteìna farnesil transferase como agentes antitumores
BR0211936A (pt) Uso de glicosamina e de um inibidor seletivo para ciclooxigenase-2, ou de pró-droga dos mesmos, na fabricação de um medicamento, bem como composição farmacêutica e kit compreendendo os mesmos
WO2010075287A3 (en) Compounds and methods for the treatment of pain and other diseases

Legal Events

Date Code Title Description
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 9A E 10A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2257 DE 08/04/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 9A, 10A, 11A, 12A, 13A, 14A, 15A E 16A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.